We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: VIVO), in connection with the proposed acquisition of the Company by SD Biosensor, Inc. (“SDB”) and SJL Partners LLC (“SJL”).  Under the merger agreement, the Company’s shareholders will receive $34.00 in cash for each share of Meridian stock owned, leaving SDB owning approximately 60% and SJL owning approximately 40% of Meridian. The transaction is valued at approximately $1.53 billion.

Weiss Law is investigating whether (i) Meridian’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $34.00 per-share merger consideration adequately compensates Meridian’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $46.00 median price target set by analysts, and at least one analyst set a price target for the Company of $62 per share, $28.00 above the per-share merger consideration.